

In the claims:

Please cancel claims 1-16.

Please add the following claims:

17. (New) A method of inducing a mean ELISA antibody titer of about 1×10^2 against ricin toxin or more in a subject comprising administering to the subject an amount of a deglycosylated ricin A-chain.

18. (New) The method of claim 1, wherein the deglycosylated ricin-A chain is chemically deglycosylated.

19. (New) The method of claim 1, wherein the deglycosylated ricin A-chain is incompletely deglycosylated.

20. (New) The method of claim 19, wherein mannose and fructose are absent from the deglycosylated ricin A-chain.

21. (New) The method of claim 17, wherein the amount is an immunogenic amount.

22. (New) The method of claim 21, wherein the immunogenic amount is about 0.1 μg to about 10.0 μg per about 20 g to about 25 g of the weight of the subject.

23. (New) The method of claim 17, wherein two doses an immunogenic amount of a deglycosylated ricin A-chain are administered to the subject.

24. (New) The method of claim 17, further comprising administering an adjuvant to the subject.

25. (New) A method for providing neutralizing antibodies against ricin toxin or preventing ricin intoxication in a subject comprising administering at least two doses of an immunogenic amount of a chemically deglycosylated ricin A-chain to the subject.

Gmt
Q2

26. (New) The method of claim 25, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

27. (New) The method of claim 26, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

28. (New) A vaccine against ricin intoxication comprising a chemically deglycosylated ricin A-chain in an immunogenic amount, wherein the immunogenic amount of the chemically deglycosylated ricin A-chain provides a mean ELISA antibody titer of about 1×10^2 or more in a subject.

29. (New) The vaccine of claim 28, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

30. (New) The vaccine of claim 28, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

31. (New) The vaccine of claim 28, wherein two doses of the immunogenic amount of the chemically deglycosylated ricin A-chain provides neutralizing antibodies in a subject.

32. (New) The vaccine of claim 28, wherein two doses of an immunogenic amount of the chemically deglycosylated ricin A-chain prevents ricin intoxication in a subject.

33. (New) A pharmaceutical composition comprising a chemically deglycosylated ricin A-chain in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant, wherein the immunogenic amount of the chemically deglycosylated ricin A-chain provides a mean ELISA antibody titer of about 1×10^2 or more in a subject.

Cat
34. (New) The pharmaceutical composition of claim 33, wherein the chemically
deglycosylated ricin A-chain is incompletely deglycosylated.

G2
35. (New) The pharmaceutical composition of claim 33, wherein mannose and
fructose are absent from the chemically deglycosylated ricin A-chain.

36. (New) An immunogenic composition comprising, in a physiologically
acceptable vehicle, a chemically deglycosylated ricin A-chain, which provides a mean
ELISA antibody titer of about 1×10^2 or more in a subject.

37. (New) The immunogenic composition of claim 36, further comprising a
adjuvant to enhance the immune response.

38. (New) The immunogenic composition of claim 36, wherein the chemically
deglycosylated ricin A-chain is incompletely deglycosylated.

39. (New) The immunogenic composition of claim 36, wherein mannose and
fructose are absent from the chemically deglycosylated ricin A-chain.

SEARCHED SERIALIZED FILED